Akebia Therapeutics
AKBA
118 hedge funds and large institutions have $392M invested in Akebia Therapeutics in 2017 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 12 closing their positions.
242% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 12
131% more call options, than puts
Call options by funds: $1.99M | Put options by funds: $863K
105% more capital invested
Capital invested by funds: $191M → $392M (+$200M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
36% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 28
33% more funds holding
Funds holding: 89 → 118 (+29)
10.54% more ownership
Funds ownership: 53.63% → 64.17% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$13.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.6M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.25M |
| 4 |
Renaissance Technologies
New York
|
+$8.1M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$7.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$4.2M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$3.84M |
| 3 |
FO
FT Options
Chicago,
Illinois
|
-$3.63M |
| 4 |
Morgan Stanley
New York
|
-$2.13M |
| 5 |
CFIC
City Financial Investment Company
London,
United Kingdom
|
-$1.74M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
JP Morgan Chase
New York
| – | -$117K | -12,650 | Closed |
|
127
LPL Financial
San Diego,
California
| – | -$90K | -10,062 | Closed |
|
128
Parallax Volatility Advisers
San Francisco,
California
| – | -$8K | -879 | Closed |
|
AKBA Hedge Fund Activity: Q2 2017 in Review
118 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2017, worth a combined $392M — up 105% from $191M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AKBA positions and 12 closed out — a net gain of 29 holders — while 38 added to existing stakes and 28 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $13.3M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $4.2M sold.
- 118 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2017, up from 89 in Q1 2017.
- Funds reported $392M of Akebia Therapeutics stock for Q2 2017, up 105% quarter-over-quarter.
- 41 funds opened new Akebia Therapeutics positions in Q2 2017 and 12 closed out, a net change of +29 holders.
- The largest Akebia Therapeutics buyer in Q2 2017 was Perceptive Advisors, an estimated $13.3M added.
- The largest Akebia Therapeutics seller in Q2 2017 was Avoro Capital Advisors, an estimated $4.2M sold.
Based on aggregated 13F filings for Q2 2017.